BMC psychiatry · 2025
Differences in cognitive deficits and brain functional impairments between patients with first-episode and recurrent depression.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guan Lianzi, Li Yifei, Kong Hui, Fang Jie, Yu Jiakuai, Wang Ting, Zhu Jiajia, Zhu Daomin
Аннотация
BACKGROUND: Accumulating evidence shows that cognitive deficits are common in patients with major depressive disorder (MDD). However, the specific differences in cognitive impairment and brain functional alterations between first-episode depression (FED) and recurrent major depression (RMD) remain unclear, as do the relationships among these factors.
METHODS: A total of 43 RMD and 41 FED patients were included in this study. All the patients underwent examinations of resting-state functional magnetic resonance imaging (fMRI), event-related potential (ERP) measurements, and a series of standardised neuropsychological tests, including event-based (EBPM) and time-based (TBPM) prospective memory tasks, the Semantic Fluency Test (SFT), and the Continuous Performance Task-Identical Pairs (CPT-IP). Two-sample t-tests were used to compare cognitive functioning, ERP parameters, and brain functional indices between FED and RMD groups. Correlation analyses were performed to explore the associations between these variables.
RESULTS: Compared with FED patients, those with RMD displayed poorer CPT-IP performance, lower prospective memory (EBPM) scores, lower SFT performance, and prolonged P300 latency (all P < 0.05). Moreover, neuroimaging data analysis revealed increased regional neural activity in the right inferior temporal gyrus (ITG), alongside decreased interhemispheric functional connectivity in the bilateral ITG in RMD relative to FED. Correlation analyses indicated that these functional changes were significantly associated with the observed cognitive deficits.
CONCLUSION: Our data demonstrated more pronounced cognitive deficits and brain functional impairments in RMD relative to FED as well as their potential links. These findings not only elucidate the neural mechanisms underlying cognitive deficits in MDD, but also inform future treatment and prevention of cognitive dysfunction in patients suffering from MDD.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: A total of 43 RMD and 41 FED patients were included in this study. All the patients underwent examinations of resting-state functional magnetic resonance imaging (fMRI), event-related potential (ERP) measurements, and a series of standardised neuropsychological tests, including event-based (EBPM) and time-based (TBPM) prospective memory tasks, the Semantic Fluency Test (SFT), and the Continuous Performance Task-Identical Pairs (CPT-IP). Two-sample t-tests were used to compare cognitive functioning, ERP parameters, and brain functional indices between FED and RMD groups. Correlation analyses were performed to explore the associations between these variables.
RESULTS: Compared with FED patients, those with RMD displayed poorer CPT-IP performance, lower prospective memory (EBPM) scores, lower SFT performance, and prolonged P300 latency (all P < 0.05). Moreover, neuroimaging data analysis revealed increased regional neural activity in the right inferior temporal gyrus (ITG), alongside decreased interhemispheric functional connectivity in the bilateral ITG in RMD relative to FED. Correlation analyses indicated that these functional changes were significantly associated with the observed cognitive deficits.
CONCLUSION: Our data demonstrated more pronounced cognitive deficits and brain functional impairments in RMD relative to FED as well as their potential links. These findings not only elucidate the neural mechanisms underlying cognitive deficits in MDD, but also inform future treatment and prevention of cognitive dysfunction in patients suffering from MDD.
CLINICAL TRIAL NUMBER: Not applicable.